Search clinical trials for: AZD5153

Total 100 results

AstraZeneca

Active, not recruiting

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study (SUPERNOVA)

COVID-19, SARS-CoV-2

United States, Belgium, Canada, France, Spain, Denmark, Thailand, Vietnam, Korea, Republic of, United Kingdom, Malaysia, Israel, Taiwan, Australia, Germany, Poland, Singapore, United Arab Emirates
AstraZeneca

Completed

AZD1152 in Patients With Advanced Solid Malignancies

Tumors

United States
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 1

Solid Tumors

Netherlands
AstraZeneca

Terminated

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

Solid Tumours

United Kingdom
AstraZeneca

Completed

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability (OAK)

Safety and Tolerability, | Advanced Solid Malignancy, | Pharmacokinetics, Pharmacodynamics, | Tumour Response,

United Kingdom, Netherlands
Oxford University Hospitals NHS Trust
University of Manchester; The Christie NHS Foundation Trust; Early Phase Cancer...

Completed

AZD1152 in Diffuse Large B-cell Lymphoma

Lymphoma

United Kingdom
AstraZeneca

Completed

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

Myeloid Leukemia

United States, Italy, Netherlands, France
AstraZeneca

Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Japan
AstraZeneca

Active, not recruiting

Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants

COVID-19, SARS-CoV-2

Japan
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
AstraZeneca
Parexel

Terminated

Evaluation of AZD8154 Concentrations in Blood

Asthma

Germany
AstraZeneca
Parexel

Recruiting

A Placebo-controlled Safety and Tolerability Study of Intravenous (IV) and Subcutaneous (SC) AZD1163 in Healthy Volunteers

Healthy Volunteers

United States, Germany
AstraZeneca

Completed

To Assess Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Effect of Fasting After Single Oral Doses of AZD5658 in Type 2 Diabetes

Type 2 Diabetes

United States
AstraZeneca

Not yet recruiting

LTFU for All Cell and Gene Therapy Studies (LOCUS)

Hepatocellular Carcinoma | Prostate Cancer

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

Healthy Participants

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 Following Single and Multiple Ascending Doses in Healthy Participants

Idiopathic Pulmonary Fibrosis

United States
AstraZeneca

Completed

A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment

Mild Cognitive Impairment | Mild Alzheimer's Disease

United States
AstraZeneca
Quintiles, Inc.

Terminated

A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United Kingdom
AstraZeneca
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Absorption to the Blood After Administration of Single and Multiple Doses of AZD8154 in Healthy Participants.

Asthma

Germany
National Cancer Institute (NCI)

Terminated

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

Gastrointestinal Neoplasms | Ovarian Neoplasms | Ovarian Cancer | Ascites | Gastrointestinal Cancer

United States
AstraZeneca

Completed

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

United Kingdom
AstraZeneca

Completed

Study to Investigate Multiple Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Healthy

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
AstraZeneca

Completed

Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder

Tourette Syndrome

United States
AstraZeneca

Active, not recruiting

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

COVID-19

United States
AstraZeneca

Completed

Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects

Healthy

United Kingdom
Institute of Cancer Research, United Kingdom
Royal Marsden NHS Foundation Trust

Unknown

A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC (RE-AKT)

Adenocarcinoma of the Prostate

United Kingdom
AstraZeneca

Completed

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer. (PYRUS)

Metastatic Castrate-Resistant Prostate Cancer (mCRPC), | Efficacy, | Safety and Tolerability, | Pharmacokinetics, | Pharmacodynamics, | Tumour Response.

United Kingdom, United States
AstraZeneca
Ionis Pharmaceuticals, Inc.

Completed

A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma

Advanced Adult Hepatocellular Carcinoma | Hepatocellular Carcinoma Metastatic

Korea, Republic of, Taiwan, Hong Kong, Japan
AstraZeneca

Active, not recruiting

Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19 (NOVELLA)

COVID-19, SARS-CoV-2

Russian Federation
AstraZeneca
Parexel

Completed

A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

Prostate Cancer

Spain, United States
AstraZeneca

Recruiting

Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors

Gastric Cancer | Pancreatic Ductal Adenocarcinoma | Esophageal Adenocarcinoma | Gastro-esophageal Junction Cancer

Korea, Republic of, United States, Japan, Taiwan, China, United Kingdom, Netherlands
University of Nottingham
AstraZeneca; Cancer Research UK; National Cancer Research Network

Completed

AKT Inhibitor in Oestrogen Positive Breast Cancer (STAKT)

Invasive Breast Cancer

United Kingdom
AstraZeneca

Active, not recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD7503 in Japanese Healthy Participants.

Heathy Participants

Japan
AstraZeneca

Completed

A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways

Bioavailability and AUC

United Kingdom
AstraZeneca

Completed

AZD5423 Multiple Ascending Dose Study

Healthy

United Kingdom
AstraZeneca

Recruiting

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA)

Ovarian Cancer | Lung Adenocarcinoma

Spain, China, United States, Australia, Taiwan, Canada, Israel, Japan, United Kingdom
AstraZeneca

Completed

Study to Investigate Single Ascending Oral Doses of AZD5213 in Healthy Male and Non Fertile Female Subjects

Tolerability

United States
AstraZeneca

Completed

Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 After Single and Multiple Ascending Oral Doses in Healthy Young and Elderly Japanese Subjects

Healthy

Japan
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
AstraZeneca

Completed

Evaluation of Histamine H3 Receptor Radioligand [11C]AZ12807110 and Histamine H3 Receptor Occupancy of AZD5213 After Oral Administration

Brain Distribution of [11C]AZ12807110 and AZD5213

Sweden
AstraZeneca

Completed

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Lymphoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Malignant Solid Tumors

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); GlaxoSmithKline; Genentech, Inc.; Brain Science...

Recruiting

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Intracranial Meningioma | Recurrent Meningioma | NF2 Gene Mutation

United States
AstraZeneca

Completed

AZD5423 Single Ascending Dose Study

Healthy Volunteers

United Kingdom
AstraZeneca

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Single and Multiple Dosing of AZD5423 in Japanese Healthy Male Subjects

Healthy

Japan
AstraZeneca
Parexel

Completed

A Study to Compare Bioavailability of AZD5055 Film-coated Tablet With AZD5055 Oral Suspension and to Assess the Effect of Food and an Acid Reducing Agent on Pharmacokinetics (PK) of AZD5055 in Healthy Subjects.

Healthy Volunteers

United States
AstraZeneca

Completed

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients (SPARK-AML1)

Acute Myeloid Leukemia

United States, Italy, United Kingdom, Romania, Japan, Australia, Germany, Spain, France
AstraZeneca

Recruiting

A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma (ATHENA)

Hepatocellular Carcinoma

United States, Korea, Republic of
Acacia Pharma Ltd

Completed

Proof-of-concept (PoC) Study of APD515

Xerostomia in Advanced Cancer Patients

United Kingdom, Denmark

Search clinical trials for: AZD5153

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations